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By analogy with successful chemotherapy regimes, it is likely that
biological therapies such as cytokines, angiostatic agents and
matrix metalloprotease inhibitors, will work best in combination.
However, this may increase toxicity without increasing efficacy.
Sequential use of biological therapies directed against different
tumour and stromal interactions may be effective and less toxic,
but guidance is needed in determining appropriate agents and
schedules. A better understanding of the effects of biological ther-
apies in the tumour microenvironment may lead to rational design
of combination biological therapy.
The cytokine interleukin-12, IL-12, has anti-tumour actions in a
range of experimental models but in these, and in clinical trials, it
has undesirable side effects. The signs of IL-12 toxicity include
splenomegaly, due to extramedullary haematopoiesis, hepatic
necrosis, lethargy and weight loss (Tare et al, 1995; Myers et al,
1998). Preclinical animal studies of IL-12 action are notable for
their detailed study of the tumour microenvironment (Tannenbaum
et al, 1996; Tsung et al, 1997; Cavallo et al, 1999), where a number
of distinct events precede tumour regression, many of which are
attributed to the local induction of IFN-γ (Nastala et al, 1994; Dias
et al, 1998a; Ogawa et al, 1998).
IL-12 induces tumour regression in mice bearing the experi-
mental murine breast cancer HTH-K (Dias et al, 1998a, 1998b)
with a distinct sequence of events including induction of IFN-γ -
inducible genes; an influx of cytotoxic T cells; apoptosis of
tumour cells and destruction/inhibition of tumour blood vessels.
The anti-angiogenic action of IL-12 in the HTH-K model involved
at least 2 mechanisms; decreased VEGF production by the tumour
cells and reduction of MMP-9 levels at the tumour site (Dias et al,
1998b). The reduction in MMP-9 was accompanied by an increase
in TIMP-1, the natural inhibitor of MMP-9. However, prolonged
IL-12 therapy, for 30 days or more, was necessary for sustained
regression and cure of mice bearing HTH-K tumour, and this was
significantly toxic (Dias et al, 1998a).
As we observed a change in the MMP/TIMP balance in the
tumour microenvironment after 14 days of IL-12 therapy, we
reasoned that a synthetic MMP inhibitor might enhance or consol-
idate the effects of IL-12 without undue toxicity. In this paper we
report that alternating cycles of IL-12 and the MMP inhibitor
Batimastat (BB94) increased therapeutic efficacy without
increasing toxicity. Administration of BB94 appeared to prevent
regeneration of tumour and stromal compartments that normally
occurs after short-term IL-12 treatment.
MATERIALS AND METHODS
Mice
Female BALB/c mice from the Specific Pathogen Free (SPF) Unit
[Clare Hall Laboratories, Imperial Cancer Research Fund (ICRF),
South Mimms, UK], 5–6 weeks of age, were used in all experi-
ments. All animal work was carried out according to the guidelines
specified by the UK Home Office Animals Scientific Procedures
Act 1986.
IL-12 and BB94
IL-12 was a gift of Stan Wolf from Genetics Institute (Cambridge,
MA) and had a specific activity of 3.3 × 106 U mg–1. IL-12 was
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Chemicals, UK) and stored at –70˚C prior to use. Mice were treated
with 1 µ g IL-12 day–1, as previously described (Dias et al, 1998a).
BB94 was kindly provided by British Biotech Pharmaceuticals
(Oxford, UK). It was diluted in 1 in 8 with dextrose for injection,
and used at a final concentration of 40 mg kg–1 day–1.
Tumour implantation
The HTH-K tumour model (a syngeneic breast carcinoma) was
transplanted subcutaneously from mouse to mouse. All treatments
were given i.p. and started 3 days after tumour implantation.
Control groups were treated with PBS containing 0.1% murine
serum albumin or BB94 diluent control (dextrose solution). The
dimensions of the subcutaneous tumours were recorded twice
weekly and mice were killed when the tumour reached a volume of
1.2 cm3. Tumour volume was calculated according to the formula
A2 × B/2 where A is length and B is width.
Protein extraction
Soluble protein was isolated from 100 mg of tissue using 2 ml of
ice-cold 1.5% (w/v) Triton-X-114 in PBS (Sigma). The tumour
sample was homogenized in 1.5% (w/v) Triton-X-114 using an
Ultra-Turrax T25 homogenizer until fully disrupted and then incu-
bated on a roller at 4˚C overnight. Any undigested tissue was
removed by centrifugation at 13 000 g for 10 min. The supernatant
was subsequently incubated at 37˚C for 5 min followed by
centrifuging at 13 000 g for 5 min. The upper aqueous phase
containing soluble proteins was removed and total protein concen-
tration was determined using the Biorad protein assay kit (Biorad,
Hemel Hempstead, UK) according to manufacturer’s instructions.
Type IV collagenolytic assay
The ability of samples to degrade type IV collagen was determined
using  3H radiolabelled type IV collagen (NEN, Boston, USA)
using the protocol described previously with minor modifications
(Fisher and Werb, 1995). Briefly 3H type IV collagen (NEN) was
dissolved in assay buffer (50 mM Tris-HCl pH 7.5 containing 
0.2 M NaCl and 10 mM CaCl2) such that each tube contained 
5 000–10 000 cpm. Samples were added and the tubes were incu-
bated at 37˚C overnight. To precipitate undigested 3H collagen,
10% (w/v) TCA containing 0.5% (w/v) tannic acid was added.
Samples were incubated on ice for 30 min followed by centrifuga-
tion at 5000 g for 15 min. Type IV collagenolytic activity was
measured by scintillation counting of the supernatant. A positive
control of 100 U ml–1 bacterial collagenase (Sigma) and a negative
control of 20 mM EDTA were employed. Collagenolytic activity
was measured in duplicate from 2 mice in each group at every time
point.
Histology and quantitative microscopy
At postmortem examination, samples were removed and fixed in
formal saline, embedded in paraffin and sectioned by the ICRF
Histopathology Unit according to standard procedures. Histology
was evaluated in haemotoxylin & eosin stained sections. The
percentage area occupied by tumour cells, stroma, blood vessels
and necrosis in tumours treated with either IL-12, BB94 or both
were analysed at various time points during tumour growth.
Sections were observed using a Nikon Labophot II microscope
(Nikon, Kingston, UK) at a magnification of × 100 (10 × objective
and 10× eyepiece) and analysed using Aequitas 1A image analysis
software (Dynamic Data Links, Cambridge, UK). Complete
sections were analysed from at least 2 mice (2 sections per mouse)
from each group at a given time point. Mean percentage area
(±SEM) occupied by tumour cells, stroma, blood vessels and
necrosis was calculated from low power observation (× 100) of the
whole section. This was between 18–50 fields of view dependent
on number of mice and size of tumour.
Statistical analysis
Statistical evaluation of survival data was estimated using either
the Cox proportional hazards model (Figure 3A and 3B) with tied
values handled by evaluating the log-likelihood function by the
exact partial method, or the stratified logrank test (Figure 2A).
Differences in tumour volumes according to treatment adminis-
tered were investigated at each measurement time by analysis of
variance (ANOVA). All statistical evaluations were performed by
Mike Bradburn at the ICRF Medical Statistics Group (Institute for
Health Sciences, Oxford, UK).
RESULTS
Treatment with IL-12 reduces MMP-9 expression and
activity
Using the technique of gelatinolytic zymography on tumour
lysates, we previously demonstrated that IL-12 inhibited MMP-9
production in the tumour microenvironment (Dias et al, 1998b).
However, during zymography, MMPs are dissociated from their
natural inhibitors. We therefore assessed the net collagenolytic
activity in the tumour microenvironment by the ability of tumour
lysates to degrade radiolabelled type IV collagen. As shown in
Figure 1, collagenolytic activity increased steadily in control mice.
At day 5 collagenolytic activity was 4-fold higher in tumours
treated with IL-12 compared with placebo. This was probably due
Therapy with IL-12 and an MMP inhibitor 1539
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Figure 1 Type IV collagenolytic activity was measured in placebo and IL-12
treated HTH-K tumours by degradation of 3H type IV collagen. Six mice were
treated with IL-12 or placebo and 2 mice per treatment were culled at each
time point. The results are representative of 2 experiments. Results were
expressed as mean radioactivity (cpm) released into the supernatantto MMP-9 production by the macrophage infiltrate which occurs
following IL-12 treatment (Dias et al, 1998a). By day 9
collagenolytic activity was not detectable in IL-12 treated tumours
but had increased 2-fold in placebo mice. At day 11 the level of
collagenolytic activity had increased to more than 10-fold the
activity in placebo mice at day 5. Once again there was no
collagenolytic activity in IL-12 treated mice at day 11.
IL-12 prolongs survival and reduces tumour volume of
HTH-K bearing mice
We previously showed that the efficacy of IL-12 was related to
length of treatment. 12 or 15 days therapy increased the survival of
HTH-K bearing mice 2- and 5-fold, but complete tumour regres-
sion was only achieved in 1/8 mice treated for 15 days compared
with 7/8 mice treated for 45 days (Dias et al, 1998a).
Figure 2A shows that the survival of HTH-K bearing mice
treated with IL-12 for 10 days was 2-fold greater than control mice
(P < 0.0001). HTH-K grew at a rapid rate in placebo mice reaching
a maximum volume of 1.2 cm3 at 10 days (Figure 2B). Tumour
growth was delayed in mice treated with IL-12 (P < 0.0001
compared with placebo and BB94-treated groups). There was a lag
period of 15 days before any major increase in tumour volume
occurred (Figure 2B).
Sequential treatment with IL-12 and BB94 enhances the
effect of IL-12
BB94 was administered for 10 days alone or after 10 days of IL-12
treatment. As a single agent, BB94 had little effect on survival of
tumour-bearing mice (Figure 2A), although a slight growth delay
and a reduction in tumour volume was noted (Figure 2B).
Sequential treatment with IL-12 (10 days) followed by BB94 (10
days) significantly increased mouse survival when compared with
IL-12 treatment alone (P = 0.05). Another treatment schedule of
IL-12 (10 days), BB94 (10 days) followed by IL-12 (10 days)
resulted in a 3.5-fold increase in survival compared to IL-12
treatment alone (data not shown, P = 0.002). At 19 days tumour
volume was significantly smaller in IL-12/BB94 (P=0.01) and
IL-12/BB94/IL-12 (P < 0.001) (data not shown) treated mice
as compared with IL-12 treatment alone. This sequential
(IL-12/BB94/IL-12) treatment resulted in 1/6 complete tumour
regressions. Similar results were seen in a second experiment with
the same schedule.
Optimization of the treatment schedule induces
complete tumour regression
The treatment cycle for each agent was then extended from 10 to
14 days. Treatment of mice with IL-12 for 14 days resulted in a 5-
fold increase in survival compared with placebo (P < 0.0001)
(Figure 3A). Once again administration of BB94 alone had little
effect on survival. Tumour-bearing mice treated with IL-12 (14
days) followed by BB94 (14 days) survived slightly longer than
mice treated with IL-12 alone with 1/12 mice obtaining complete
tumour regression (Figure 3B). 29 days after the start of therapy
1/12 (IL-12), 4/12 (IL-12/BB94) and 6/12 (IL-12/BB94/IL-12)
mice were still alive (significant difference between IL-12 treated
and sequential treatments at 29 days P = 0.04). It is important to
note that had a group been included with the schedule IL-12 (14
days), placebo (14 days) and another dose of IL-12 for 14 days
there would have only been one mouse to treat by the time the
second IL-12 cycle was due.
Thus the influential time for survival appears to be between 10
and 15 days after the first cycle of IL-12 was completed. BB94
enables some mice to survive through this period by preventing
tumour regrowth.
The most potent schedule was IL-12/BB94/IL-12 (in 14 day
cycles). Survival of mice was significantly prolonged compared
with mice treated with 14 daily administrations of IL-12 (P =
0.002) and IL-12/BB94 treated mice (P = 0.03) (Figure 3B). At 38
days 6/12 mice were still alive in this treatment group compared
with 0/12 mice treated with IL-12 alone. 4 mice (out of the 6/12
still alive at 38 days) achieved complete tumour regression and
had no recurrence of disease after 300 days.
Sequential treatment of IL-12 and BB94 results in
angiogenesis blockade
Examination of H&E stained tumour sections from mice receiving
the different treatment schedules suggested that BB94 might be
delaying the regeneration of the tumour tissue that generally
1540 KA Scott et al
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Figure 2 Survival and tumour volume of HTH-K bearing mice. Six mice per group were treated with one of the following schedules: placebo, IL-12 10 days,
BB94 10 days, IL-12 10 days followed by BB94 10 days. Percentage survival of HTH-K bearing mice (A). HTH-K tumour volume measured as described in
materials and methods (B)occurs after the cessation of short-term IL-12 therapy. This was
confirmed by image analysis and quantitation of the areas occu-
pied by tumour cells, stroma, necrosis or large blood vessels in
tumour sections examined at low power. As shown in Figure 4,
treatment with BB94 alone for 10 days had little effect on the
composition of the tumour compared to placebo mice (data not
Therapy with IL-12 and an MMP inhibitor 1541
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Figure 3 Percentage survival of HTH-K tumour bearing mice following optimization of sequential therapy. Treatment schedules were extended to 14 days;
placebo, IL-12 14 days, IL-12 14 days followed by BB94 14 days, IL-12 14 days followed by BB94 14 days followed by IL-12 14 days. Each group contained 12
mice. Percentage survival of HTH-K bearing mice treated with a single agent (A). Percentage survival of HTH-K bearing mice with sequential treatments (B)
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Figure 4 Analysis of tumour composition following sequential treatments. Percentage areas occupied by tumour cells, stroma, blood vessels and necrosis
were measured from haemotoxylin and eosin stained sections as described in materials and methods. Complete sections were analysed from at least 2 mice 
(2 sections per mouse) from each group at a given time point. This was between 18–50 fields of view. Results were expressed as mean % area (±SEM)1542 KA Scott et al
British Journal of Cancer (2000) 83(11), 1538–1543 © 2000 Cancer Research Campaign
shown). The necrotic areas were small and the stromal content was
slightly increased compared with IL-12 treated tumours (11.5%
versus 5% at 10 days). Tumours from IL-12 treated mice showed
signs of regression between 10 and 14 days of therapy. The mean
area occupied by epithelial tumour cells decreased from 35% to
15%. By 14 days a mean of 68% of the tumour area was occupied
by necrosis and the large blood vessels that characterize this
tumour were absent. The effects of IL-12 on the tumour micro-
environment were, however, reversible. Seven days after the
cessation of IL-12 treatment (day 21), the percentage tumour cell
area had increased approximately 4-fold from 15% to 56%; the
areas of necrosis were reduced 10-fold from 58% to 6% and new
blood vessels had been formed (0% to 4.5% of total area) (Figure 4
and Figure 5A).
When BB94 was administered after IL-12 treatment this regen-
eration of tumour tissue was not seen either after 21 or 26–28 days;
52% of the tumour was still necrotic and large blood vessels had
not re-formed (Figure 4 and Figure 5B).
DISCUSSION
Systemic IL-12 administration successfully modulates the 
tumour microenvironment leading to regression and cure in a
variety of tumour models (Oshikawa et al, 1999; Seetharam et al,
1999; Silver et al, 1999; Mazzolini et al, 2000) but its use in
animals and human patients is limited by toxicity. In the HTH-K
breast carcinoma, IL-12 therapy led to tumour regression by
increasing IFN-γ production, promoting tumour cytotoxic 
T-cell infiltrates and producing an anti-angiogenic response (Dias
et al, 1998a). The latter involved reduction of VEGF protein, an
induction of IP-10 at the tumour site, decreased MMP-9 produc-
tion and increased local release of its inhibitor TIMP-1 (Dias et al,
1998b).
Since one of the changes induced by IL-12 in the tumour
microenvironment was the modulation of MMP-9 and TIMP-1, we
suggested that sequential administration of a synthetic MMP
inhibitor after IL-12 treatment might produce similar anti-tumour
effects with a significant reduction in toxicity.
BB94 is a broad range MMP inhibitor with reported anti-tumour
effects in other tumour models (Low et al, 1996; Prontera et al,
1999; Wylie et al, 1999). Its mechanisms of action are not fully
understood, but because of its MMP-blocking activities it may
change the stromal content of solid tumours and create a solid
capsule around the developing tumour (Davies et al, 1993).
Sequential treatment of HTH-K bearing mice with IL-12
followed by BB94 produced anti-tumour effects resulting in an
overall survival increase compared with mice treated with IL-12
alone. Tumours treated with this combination had increased
tumour necrosis, decreased tumour and stromal areas and were
less vascularized than tumours treated with IL-12 alone. Because
BB94 alone produced only marginal anti-tumour effects, these
results suggest that the combination produced synergistic rather
than additive effects. The most significant effect of BB94 adminis-
tration was to delay tumour regrowth following cessation of IL-12
therapy. Tumours treated with IL-12 alone began to recover 7–10
days after therapy was stopped as characterized by an increase in
blood vessels and reduction in necrosis.
Overall, the increase in survival and the anti-tumour effects in
the combination group were similar to those seen with prolonged
IL-12 therapy alone (Dias et al, 1998a). Prolonged daily IL-12
therapy for more than 14 days of HTH-K induced signs of toxicity.
Lethargy, increased coat ‘ruffling’, and in some cases, minor
weight loss were observed. Moreover, splenomegaly due to
extramedullary haematopoiesis and hepatic necrosis were also
observed by histology. In mice treated with 14 day cycles of IL-12
and BB94 the signs of toxicity were less pronounced. Lethargy and
coat changes were not seen, no weight loss was observed and
hepatic necrosis was reduced. Moreover, in mice treated with 
IL-12/BB94/IL-12 signs of toxicity were detected after 14 days of
IL-12 treatment but were reduced during MMPI administration.
Therefore, mice could be treated once more with IL-12 without a
corresponding increase in toxicity.
MMPs have been implicated in angiogenesis (Hiraoka et al,
1998; Sang, 1998; Kraling et al, 1999), and because of its MMP
blocking effects it has been suggested that BB94 might have
potent anti-angiogenic effects. Moreover, in the HTH-K model a
decrease in VEGF levels correlated with a reduction in tumour
vascularity after prolonged IL-12 treatment (Dias et al, 1998b).
Following short-term IL-12 treatment blood vessel regrowth
occurred. This was blocked by sequential treatment with BB94
Figure 5 H&E sections of tumours treated with IL-12 or IL-12/BB94 at 21 days. Tumours treated for 14 days with IL-12 (A) show regeneration of blood vessels
(arrows) and tumour cell islands (T) surrounded by stroma (S). Sequential treatment with BB94 (B) prevented blood vessel regrowth and maintained the high
level of necrosis (N) observed at 14 days of IL-12 therapy. Tumour islands were still present following sequential treatment with BB94Therapy with IL-12 and an MMP inhibitor 1543
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indicating that at least 1 metalloenzyme (MMP-9) is crucial for
angiogenesis in the HTH-K model. Other MMPs or adamalysin
metalloproteinases may also be involved. Preliminary data
suggests that BB94 also reduced the levels of VEGF within the
tumour. We found that tumours which are responsive to BB94 (i.e.
no significant increase in tumour volume) contain almost 4-fold
lower VEGF levels compared with non-responsive tumours
treated with IL-12/BB94 or those treated with IL-12 alone (data
not shown).
BB94 may modulate the tumour extracellular matrix composi-
tion and upon contact with different ECM components, VEGF
production by tumour cells may be reduced. Alternatively, since it
has been shown that VEGF binds ECM and can be released by
proteolytic cleavage (Park et al, 1993), inhibition of MMP activity
by BB94 may lead to the accumulation of VEGF in the ECM
making it unavailable for the proliferating tumour endothelium. 
In the absence of VEGF the tumour endothelial cells undergo
apoptosis (Benjamin and Keshet, 1997), halting the angiogenic
process and thus limiting tumour growth. This mechanism of
action of BB94 has been recently suggested (Bergers et al, 1999).
Investigation into the efficacy of BB94 in the RIP1-Tag2 model of
pancreatic islet cell carcinogenesis revealed that inhibition of
MMP activity reduced the incidence of angiogenic switching in a
prevention trial but could only slow tumour growth when adminis-
tered after tumour establishment had occurred (Bergers et al,
1999). In the HTH-K model, BB94 did not significantly prolong
survival alone but could slow tumour recovery following treat-
ment with IL-12.
This, to our knowledge is the first report of combination of an
MMP inhibitor with IL-12. We suggest that detailed studies of
tumour microenvironment changes may lead to the design of
successful biological therapy combinations to target different
tumour–stroma interactions.
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